In addition to the tyrosine kinase inhibitors targeting VEGF pathways, studies have shown that a combination of targeted therapeutics plus immunotherapy agents can nearly double the survival of patients with RCC.72 The gene discussed is VEGFA; the disease is renal cell carcinoma.